Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma. Lu Y, Liao L, Du K, Mo J, et al. BMC Cancer 2024;24:133.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lu Y, Liao L, Du K, Mo J, et al. Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma. BMC Cancer 2024;24:133.
PMID: 38273249